Investigational drug · Phase 3
VK2735
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Weight Loss.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
8
Any phase or sponsor naming "VK2735"
First trial start
2024
Dec 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VK2735", any sponsor or status.
Conditions studied
As listed on its trial records.
- Weight Loss
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "VK2735" as an intervention, largest first.
- VK2735 for Weight Management Phase 3Pivotal-lookingActive, not recruiting
Viking Therapeutics, Inc.Industry
NCT07104500 · 4,500 participants (planned) · Start Jun 23, 2025 · Primary completion Jul 1, 2027
Drug: VK2735 · For: Weight Loss
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 137 sites in all
- VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)Pivotal-lookingActive, not recruiting
Viking Therapeutics, Inc.Industry
NCT07104383 · 1,100 participants (planned) · Start Jun 23, 2025 · Primary completion Jul 1, 2027
Drug: VK2735 · For: Weight Loss
Sites: Birmingham, Alabama; Huntsville, Alabama; Chandler, Arizona · 127 sites in all
- Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)Pivotal-lookingRecruiting
Viking Therapeutics, Inc.Industry
NCT07868835 · 560 participants (planned) · Start Nov 2026 · Primary completion Jul 2028
Drug: VK2735; Placebo comparator · For: Weight Loss
Sites: Tucson, Arizona; Chula Vista, California; Lake Forest, California · 20 sites in all
- Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)Pivotal-lookingRecruiting
Viking Therapeutics, Inc.Industry
NCT07868939 · 560 participants (planned) · Start Nov 2026 · Primary completion Oct 2028
Drug: VK2735 Oral; Placebo Comparator · For: Weight Loss
Sites: Tucson, Arizona; Lake Forest, California; Ocoee, Florida · 19 sites in all
- VK2735 for Weight Management Phase 2 (Venture Oral Dosing)Pivotal-lookingCompleted
Viking Therapeutics, Inc.Industry
NCT06828055 · 280 participants · Start Dec 18, 2024 · Primary completion Jun 24, 2025
Drug: Placebo; VK2735 · For: Weight Loss
Sites: Peoria, Arizona; Lake Forest, California; Clearwater, Florida · 15 sites in all
- A Phase 1 Study of VK2735 in Obese Adults Without ComorbiditiesPivotal-lookingRecruiting
Viking Therapeutics, Inc.Industry
NCT07838740 · 270 participants (planned) · Start Nov 18, 2025 · Primary completion May 2027
Drug: VK2735 Drug; Placebo · For: Obese Adults
Sites: Lake Forest, California; Miami, Florida
- VK2735 for Weight Management Phase 2Pivotal-lookingCompleted
Viking Therapeutics, Inc.Industry
NCT06068946 · 176 participants · Start Aug 31, 2023 · Primary completion Feb 27, 2024
Drug: VK2735; Placebo · For: Weight Loss
Sites: Birmingham, Alabama; Long Beach, California; Los Angeles, California · 20 sites in all
Viking Therapeutics, Inc.Industry
NCT05203237 · 92 participants · Start Dec 14, 2021 · Primary completion Nov 4, 2024
Drug: VK2735; Placebo and 2 more · For: Weight Loss; NASH
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
- Future GLP-1 receptor co-agonists and their cardiac effects.
Neumann J, Kirchefer U, Hofmann B, et al. · Naunyn Schmiedebergs Arch Pharmacol 2026
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.
Bays HE, Toth P, Alkhouri N, et al. · Obesity (Silver Spring) 2026
Also in development for Weight Loss
- AleniglipronPhase 36 trials
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics · Obesity, Overweight, Chronic Weight Management
- RilogrotugPhase 31 trial
AVEO Pharmaceuticals, Inc. · Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.